SONIRE Therapeutics Inc.
June 16, 2025
Company Presentation
Oncology
SONIRE is a Tokyo-based startup founded in February 2020, developing an ultrasound-guided HIFU therapy system using technology (Code Name: Suizenji) created at Tohoku University. Suizenji delivers focused ultrasound energy from outside the body, enabling non-invasive treatment without skin incisions or organ removal. Suizenji is designed to allow treatment without anesthesia and poses no radiation exposure risk, unlike conventional therapies involving ionizing radiation.
SONIRE is conducting a clinical trial for pancreatic cancer in Japan and preparing a clinical trial in the U.S. in 2025 using Suizenji. Suizenji has been designated as a Breakthrough Device by the FDA for the treatment of pancreatic cancer in October 2024. Looking ahead, SONIRE is planning to expand both the geographic reach and the clinical indications of its HIFU therapy system.
Company HQ City:
Chuo-ku
Company HQ State:
Tokyo
Company HQ Country:
Japan
Year Founded:
2020
Lead Product in Development:
an ultrasound guided HIFU therapy system (Development Code: Suizenji)
CEO
Tohru Satoh, President & CEO, Founder
Development Phase of Lead Product
Phase II
When you expect your next catalyst update?
Complete enrollment of the randomized controlled trial for pancreatic cancer in Japan (SUNRISE-I Study), and initiate a clinical trial for pancreatic cancer in the U.S. as well as a trial for another indication in Japan.
What is your next catalyst (value inflection) update?
All catalyst events are expected to occur within this year.
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}